Research ArticleOriginal Article

The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma

Yan Song, Juxiang Xiao, Wentao Fang, Ping Lu, Qingxia Fan, Yongqian Shu, Jifeng Feng, Shu Zhang, Yi Ba, Yang Zhao, Ying Liu, Chunmei Bai, Yuxian Bai, Yong Tang, Jie He and Jing Huang
Cancer Biology & Medicine May 2021, 18 (2) 562-568; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0187

References

  1. 1.↵
    2. Bray F,
    3. Ferlay J,
    4. Soerjomataram I,
    5. Siegel RL,
    6. Torre LA,
    7. Jemal A.
    Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394–424.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Chen W,
    3. Zheng R,
    4. Zhang S,
    5. Zhao P,
    6. Li G,
    7. Wu L, et al.
    Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013; 25: 10–21.
    OpenUrlPubMed
  3. 3.↵
    2. Ajani JA,
    3. D’Amico TA,
    4. Bentrem DJ,
    5. Chao J,
    6. Corvera C,
    7. Das P, et al.
    Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17: 855–83.
    OpenUrlCrossRefPubMed
  4. 4.↵
    2. Hayashi K,
    3. Ando N,
    4. Watanabe H,
    5. Ide H,
    6. Nagai K,
    7. Aoyama N, et al.
    Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol. 2001; 31: 419–23.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    2. Huang J,
    3. Zhou Y,
    4. Zhang H,
    5. Qu T,
    6. Mao Y,
    7. Zhu H, et al.
    A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy. Med Oncol. 2013; 30: 343.
    OpenUrl
  6. 6.↵
    2. Syed YY.
    Anlotinib: first global approval. Drugs. 2018; 78: 1057–62.
    OpenUrlCrossRefPubMed
  7. 7.↵
    2. Han B,
    3. Li K,
    4. Wang Q,
    5. Zhang L,
    6. Shi J,
    7. Wang Z, et al.
    Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018; 4: 1569–75.
    OpenUrl
  8. 8.↵
    2. Kashyap MK,
    3. Abdel-Rahman O.
    Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma. Mol Cancer. 2018; 17: 54.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Huang J,
    3. Xiao J,
    4. Fang W,
    5. Lu P,
    6. Fan Q,
    7. Shu Y, et al.
    Anlotinib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma (ESCC): a randomized, double-blind, multicenter phase II trial. J Clin Oncol. 2019; 37(4 Suppl): S95.
  10. 10.↵
    2. George S,
    3. Reichardt P,
    4. Lechner T,
    5. Li S,
    6. Cohen DP,
    7. Demetri GD.
    Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol. 2012; 23: 3180–7.
    OpenUrlCrossRefPubMed
  11. 11.
    2. Bono P,
    3. Rautiola J,
    4. Utriainen T,
    5. Joensuu H.
    Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol. 2011; 50: 569–73.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.
    2. Dahlberg SE,
    3. Sandler AB,
    4. Brahmer JR,
    5. Schiller JH,
    6. Johnson DH.
    Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol. 2010; 28: 949–54.
    OpenUrlAbstract/FREE Full Text
  13. 13.
    2. Scartozzi M,
    3. Galizia E,
    4. Chiorrini S,
    5. Giampieri R,
    6. Berardi R,
    7. Pierantoni C, et al.
    Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009; 20: 227–30.
    OpenUrlCrossRefPubMed
  14. 14.↵
    2. Wirth LJ,
    3. Tahara M,
    4. Robinson B,
    5. Francis S,
    6. Brose MS,
    7. Habra MA, et al.
    Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer. 2018; 124: 2365–72.
    OpenUrl
  15. 15.↵
    2. Wang J,
    3. Zhao Y,
    4. Wang Q,
    5. Zhang L,
    6. Shi J,
    7. Wang Z, et al.
    Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment. Cancer Biol Med. 2018; 15: 443–51.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    2. Wang ZH,
    3. Han B,
    4. Li K,
    5. Cheng Y,
    6. Liu J,
    7. Guo J, et al.
    Clinical outcomes of patients with or without common AEs in anlotinib cohort: Subgroup analysis of the ALTER0303 trial. J Clin Oncol. 2019; 37: e20507.
  17. 17.↵
    2. Fang Z,
    3. Chi Y,
    4. Yao Y,
    5. Wang S,
    6. Huang G,
    7. Cai Q, et al.
    Evaluation of hypertension and hand-foot syndrome as markers of anlotinib efficacy in advanced soft tissue sarcoma. Ann Oncol. 2018; 29: viii587.
    OpenUrl
  18. 18.↵
    2. Chi Y,
    3. Gao M,
    4. Tang P,
    5. Zheng X,
    6. Xu Z,
    7. Li D, et al.
    Exploration of associations between adverse drug reactions and clinical outcomes in anlotinib treatment against medullary thyroid carcinoma (MTC): a subgroup analysis based on the ALTER01031 trial. J Clin Oncol. 2020; 38: e18518.
  19. 19.↵
    2. Eisenhauer EA,
    3. Therasse P,
    4. Bogaerts J,
    5. Schwartz LH,
    6. Sargent D,
    7. Ford R, et al.
    New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228–47.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    2. Rini BI,
    3. Cohen DP,
    4. Lu DR,
    5. Chen I,
    6. Hariharan S,
    7. Gore ME, et al.
    Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011; 103: 763–73.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    2. Eechoute K,
    3. van der Veldt AA,
    4. Oosting S,
    5. Kappers MH,
    6. Wessels JA,
    7. Gelderblom H, et al.
    Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther. 2012; 92: 503–10.
    OpenUrlPubMed
  22. 22.
    2. Jain L,
    3. Sissung TM,
    4. Danesi R,
    5. Kohn EC,
    6. Dahut WL,
    7. Kummar S, et al.
    Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res. 2010; 29: 95.
    OpenUrlCrossRefPubMed
  23. 23.↵
    2. Kim JJ,
    3. Vaziri SA,
    4. Rini BI,
    5. Elson P,
    6. Garcia JA,
    7. Wirka R, et al.
    Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer. 2012; 118: 1946–54.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    2. Schneider BP,
    3. Wang M,
    4. Radovich M,
    5. Sledge GW,
    6. Badve S,
    7. Thor A, et al.
    Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008; 26: 4672–8.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    2. Sibertin-Blanc C,
    3. Mancini J,
    4. Fabre A,
    5. Lagarde A,
    6. Del Grande J,
    7. Levy N, et al.
    Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer. Dig Liver Dis. 2015; 47: 331–7.
    OpenUrl
  26. 26.↵
    2. Cheng Y,
    3. Wang Q,
    4. Li K,
    5. Shi J,
    6. Wu L,
    7. Han B, et al.
    Anlotinib as third-line or further-line treatment in relapsed SCLC: A multicentre, randomized, double-blinded phase 2 trial. J Thorac Oncol. 2018; 13: S351–2.
    OpenUrl
  27. 27.↵
    2. Zhou AP,
    3. Bai Y,
    4. Song Y,
    5. Luo H,
    6. Ren XB,
    7. Wang X, et al.
    Anlotinib Versus sunitinib as first-line treatment for metastatic renal cell carcinoma: a randomized phase II clinical trial. Oncologist. 2019; 24: e702–8.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    2. Ma J,
    3. Song Y,
    4. Shou J,
    5. Bai Y,
    6. Li H,
    7. Xie X, et al.
    Anlotinib for patients with metastatic renal cell carcinoma previously treated with one vascular endothelial growth factor receptor-tyrosine kinase inhibitor: a phase 2 trial. Front Oncol. 2020; 10: 664.
    OpenUrl
  29. 29.↵
    2. Bamias A,
    3. Lainakis G,
    4. Manios E,
    5. Koroboki E,
    6. Gyftaki R,
    7. Zakopoulos N, et al.
    Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib. J Chemother. 2009; 21: 347–50.
    OpenUrlPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords